BioCryst Q4 ORLADEYO revenue $70.7M; FY 2022 revenue $270.8M; 2023 guidance ≥$320M

BIOCRYST PHARMACEUTICALS INC

2022-FY EPS reported -$1.33 revenue$270,827,000

ORLADEYO net revenue $70.7M in Q4 2022, $251.6M for FY 2022; 2023 guidance no less than $320M.
Total Q4 revenue $79.5M (+68% YoY); net loss $71.5M ($0.38/share) vs $17.8M ($0.10) in Q4 2021 (incl. $55.8M gain).
Full year net loss $247.1M ($1.33/share) vs $184.1M ($1.03) in 2021; cash $443.9M at Dec 31, 2022.
Complement inhibitor program delayed due to nonclinical study observations; BCX10013 phase 1 showed >97% AP suppression.
ORLADEYO peak sales expected $1B; Canadian positive reimbursement recommendation received.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOCRYST PHARMACEUTICALS INC reported the fourth quarter and full year ended December 31, 2022 results: revenue $79.5 million, net income $71.5 million, or $0.38 per share, EPS $0.38 per share. Guidance reaffirmed.

Period: the fourth quarter and full year ended December 31, 2022
Revenue: $79.5 million
Net income: $71.5 million, or $0.38 per share
EPS: $0.38 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

molecules targeting C2, which are currently in lead optimization. Fourth Quarter 2022 Financial Results For the three months ended December 31, 2022, total revenues were $79.5 million, compared to $47.2 million in the fourth quarter of 2021 (+68 percent year-over-year). The increase was primarily due to $70.7 million in ORLADEYO net revenue in the fourth

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-23-001058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.